Personalized medicine – genomic phase
Authors:
R. Brdička
Authors place of work:
Ústav hematologie a krevní transfuze a Ústav experimentální medicíny AV ČR, Praha
Published in the journal:
Čas. Lék. čes. 2009; 148: 477-480
Category:
Topic
Summary
Personalized medicine has become declared to be a strategic goal of nearly all medical disciplines, a modern fashion of medicine, which corresponds to unexpected progress in knowledge of structure and sometimes also understanding the function of our genome. This was made possible by development of new technologies and methodological approaches, which led to improved and more detailed diagnostics and categorization of diseases Also pharmaceutical industry is producing many new drugs, but not all are effective as supposed, and sometimes also cause adverse reactions (ADR). To prevent uneffectiveness and ADR, preliminary genetic testing of patients seems to be necessary. Utility of personalized medicine is sometimes discussed from the point of view of supposed inevitable increase of cost and problems with its adoption by existing system of healthcare.
Key words:
molecular diagnostics, interindividual differences, rare diseases, breast cancer, favism, pharmacogenomics, targeted therapy, adverse reactions, economics.
Zdroje
1. Sharp AJ. Emerging Themes and new challenges in defining the role of strctural variation in human disease. Human Mutation 2008; 30: 1–10.
2. Antonacci F, et al. Characterization of six human disease–associated inversion polymorphisms. Hum Mol Genet. 2009; 18: 2555–2663.
3. Miki Y, et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66–71.
4. Wooster R, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265: 2088–2090.
5. Wang B, et al. NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control. Genes Dev. 2009; 23: 729–739.
6. Ripperger T, et al. Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet 2009; 17: 721–731.
7. Beggs AD, Hodgson SV. Genomics and breast cancer: The different levels of inherited susceptibility European Journal of Human Genetics 2009; 17: 855–856.
8. Tan-Chiu E, Piccart M. Moving forward: Herceptin in the adjuvant setting. Oncology 2002; 63 (Suppl. 1): 57–63.
9. Baselga J, et al. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist. 2006; 11 (Suppl. 1): 4–12.
10. Grell P, et al. Trastuzumab in the breast cancer treatment: Efficacy and resistance mechanisms Klinická Onkologie 2009; 22: 45–51.
11. Li Y, et al. Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo Cancer Letters 2009; 279: 213–220.
12. Grosso S, et al. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. Mol Cancer Ther 2009; 8: 1924–1933.
13. Atkins MB, et al. Everolimus. Nat Rev Drug Discov. 2009; 8: 535–536.
14. Böck S, et al. Significance of monoclonal antibodies and oral tyrosine kinase inhibitors in the treatment of advanced pancreatic carcinoma Deutsche Zeitschrift fur Onkologie 2008; 40: 100–105.
15. Hogan KJ, et al. Perioperative genomic profiles using structure-specific oligonucleotide probes. Clin Med Res 2009; PMID 19474452.
16. Zhou SF, et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 2008; 9: 738–784.
17. Gurwitz D, et al. Pharmacogenomics education: International Society of Pharmacogenomics. Reccomendations for medical, pharmaceutical, and health schools deans of education. The Pharmacogenomics J 2005; 5: 221–225.
18. Daar AS, Singer PA. Pharmacogenetics and geographical ancestry: implications for drug development and global health. Nature Rev.Genetics 2005; 6: 241–246.
19. Becquemont L: Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Pharmacogenomics 2009; 109: 61–969.
20. Noori-Daloii MR, Daneshpajooh M. Molecular basisi of G6PD deficienty: current status and its perspektive. Acta medica Iranica 2008; 46: 167–182.
21. Schuurman M, et al. Severe hemolysis and methemoglobinemia following fava beans ingestion in glukose-6-phosphate dehydrogenace deficienty – case report and literature review. Eur J Pediatr 2009; 168: 779–782.
22. Votava F, Strnadová K. Novorozenecký screening v České republice a v Evropě. Čes-slov Pediatr 2008; 63: 96–105.
23. Searle R, Hopkins PM. Pharmacogenomic variability and anaesthesia. Br J Anaesth 2009; 103: 14–25.
24. Restrepo JG, et al. Polymorphic drug metabolism in anaesthesia Current Drug Metabolism 2009; 10: 236–246.
25. Wimmers K. Inherited disorders in pigs: Status of molecular genetic characterisation and future directions (in German) Zuchtungskunde 2008; 80: 35–42.
26. Leeder JS, Spielberg SP. Personalized medicine: Reality and reality checks. Annals of Pharmacotherapy 2009; 43: 963–966.
27. Garber AM, Tunis SR. Does komparative-effectiveness research threaten personalized medicine? New England J Med 2009; 360: 1925–1927.
28. Lee SS, Muduliar A. Racing forvard:The genomic and personalized medicíně act. Science 2009; 323: 342.
29. Garrison LP. Will pharmacogenomics disrupt the U.S. health care systém? Public health genomics 2009; 12; 185–190.
30. Dean CE: Personalized medicine: Boon or budget-buster? Annals of Pharmacotherapy 2009; 43: 958–962.
31. Issa AM, et al. Assessing patient readiness for the clinical adoption of personalized medicine. Public Health Gernomics 2009; 12: 163–169.
32. Davis JC, et al. The microeconomics of personalized medicine: Today‘s challenge and tomorrow‘s promise. Nature Reviews Drug Discovery 2009; 8: 279–286.
33. Lau K-C, et al. A fast modified protocol for random-access ultra-high density whole-genome scan: A tool for personalized genomic medicine, positional mapping, and cytogenetic analysis Clinica Chimica Acta 2009; 406: 31–35.
34. Deeken J. The Affymetrix DMET platform and pharmacogenetics in drug development. Curr Opin Mol Ther 2009; 11: 260–268.
35. Pospíšilová Š, et al. Sekvenování lidského geonomu – technologie nové generace aneb budeme rutinně sekvenovat lidské genomy? Čas Lék čes 2009; 148: 296–302.
36. Russell J. Celera pushes boundaries with automated worlflow, http://www.bio-itworld.com/pb/2009/07/16/celera-pioneers-workflow-use.html
37. Robertson GR, Piquette-Miller M. Pharmacogenetics of pharmacoecology: Which route to personalized medicíne? Clin pharmacology and therapeutics 2009; 85: 343–348.
38. Brand A. Integrative genomics, personal-genome tests and personalized healthcare: the future is being built today. Eur J Hum Gneter 2009; 17: 977–978.
39. Hudson TJ. Personalized medicine: A transformative approach is needed. CMAJ 2009; 180: 911–913.
Internetové adresy:
http://www.personalizedmedicinecoalition.org/
http://www.p3g.org/
http://www.p3gconsortium.org/
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- Intravenous treatment with iron in bloodless medicine
- Low molecular weight heparins and their non-antithrombotic effects on wound healing
- Compliance in psychiatry
- Therapeutic plasma exchange in the treatment of the hereditary thrombotic thrombocytopenic purpura